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Abstract: PTEN is a dual-specificity protein tyrosine phos-
phatase. As one of the central tumor suppressors, a thorough
regulation of its activity is essential for proper cellular homeo-
stasis. The precise implications of PTEN inhibition by reactive
oxygen species (e.g. H2O2) and the subsequent structural
consequences remain elusive. To study the effects of PTEN
inhibition, bisperoxidovanadium (bpV) complexes serve as
important tools with the potential for the treatment of nerve
injury or cardiac ischemia. However, their mode of action is
unknown, hampering further optimization and preventing
therapeutic applications. Based on protein crystallography,
mass spectrometry, and NMR spectroscopy, we elucidate the
molecular basis of PTEN inhibition by H2O2 and bpV
complexes. We show that both molecules inhibit PTEN via
oxidative mechanisms resulting in the formation of the same
intramolecular disulfide, therefore enabling the reactivation of
PTEN under reductive conditions.
PTEN (phosphatase and tensin homologue deleted on
chromosome 10) is a member of the protein tyrosine
phosphatase (PTP) superfamily and one of the most impor-
tant tumor suppressors.[1] In addition, it constitutes a critical
factor in regenerative processes.[2] These implications are
mainly associated with the inhibitory effect on AKT signaling
which is conveyed by its lipid phosphatase activity.[1] PTEN
function is tightly regulated by posttranslational modifica-
tions such as phosphorylation, ubiquitination, and oxida-
tion.[1, 3] PTEN and a number of other PTPs harbor an active
site with a characteristic phosphate-binding loop (P-loop:
[I/V]HCXXGXXR[S/T]) involving a deprotonated catalytic
cysteine,[4, 5] which is particularly susceptible to oxidation.[6] In
a cellular context, reactive oxygen species (e.g. H2O2)
[7] can
trigger the oxidation of thiols to sulfenic acid, which can
either be irreversibly oxidized to sulfinic and sulfonic acid[6] or
react with properly aligned nucleophiles (e.g. thiols and
activated amides) to form reversible modifications such as
disulfides and sulfenyl-amides (Figure 1a).[6] Importantly,
these reversible modifications constitute a protective mech-
anism preventing irreversible impairment of phosphatase
activity.[6] In the case of PTEN, H2O2 inhibits phosphatase
activity by triggering the formation of a disulfide bond
between catalytic cysteine C124 and closely aligned cysteine
C71.[8–10] So far, the structural consequences of this oxidation
remain elusive.
PTEN inhibition and subsequent activation of prosurvival
signaling stimulates cellular regeneration thereby promoting
axonal regrowth and neural survival.[11] Therefore, PTEN
inhibition is considered a therapeutic approach in response to
nerve injury and cardiac ischemia. Bisperoxidovanadium
(bpV, also: bisperoxovanadium) complexes inhibit PTEN
activity and serve as model compounds to study these
implications.[12–16] The precise mode of action of bpV inhib-
itors is under debate,[13, 16] and its elucidation can support
further optimization campaigns. To obtain structural insight
into PTEN inhibition by H2O2 and bpV complexes, we
applied protein crystallography, mass spectrometry (MS), and
Figure 1. a) H2O2 triggers oxidation of thiols to sulfenic acid, which
can react with nucleophiles to form reversible modifications, or it
reacts irreversibly to yield sulfinic as well as sulfonic acid (PTP: protein
tyrosine phosphatase). b) Chemical structure of bpV-phen (potassium
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51V NMR spectroscopy. Strikingly, both molecules inhibit
PTEN by oxidative mechanisms that result in the formation
of the same disulfide-bridged PTEN species. In both cases,
disulfide formation is reversible under reductive conditions.
Initially, phosphatase activity of full-length PTEN was
investigated using the malachite green assay with phosphati-
dylinositol trisphosphate (PI(3,4,5)P3) as substrate. Half-
maximal inhibitory concentrations (IC50) of H2O2 and bpV-
phen (Figure 1b) were determined providing values in agree-
ment with previous reports (H2O2 : (60 23) mm, bpV-phen:
(0.18 0.02) mm, Figure S2 in the Supporting Informa-
tion).[8, 12] To verify the reversibility of PTEN inhibition
under reductive conditions, PTEN was pretreated with H2O2
(3.5 mm) and then diluted with buffer either lacking reducing
agent (mock), or containing dithiothreitol (DTT, 4 mm) and
glutathione (GSH, 4 mm), respectively (Figure 2a). In the
absence of reducing agent, efficient PTEN inhibition is
observed (residual phosphatase activity: (8 4)%) while
addition of DTT or GSH resulted in reactivation (phospha-
tase activity: (99 3)% and (73 4)%, respectively). Given
the presence of peroxido ligands in bpV-phen and the so far
unknown inhibitory mechanism, we tested whether PTEN
inhibition by bpV-phen can also be reversed under reductive
conditions. Again, PTEN inhibition (residual phosphatase
activity: (4 4)%) was abolished after DTT or GSH treat-
ment (phosphatase activity: (95 7)% or (69 5)%) indicat-
ing oxidative inhibition by bpV-phen (Figure 2a).
H2O2 triggers disulfide formation between PTENÏs active
site cysteines C124 and C71.[8] To investigate whether bpV-
phen treatment results in the same disulfide, we performed
HPLC-coupled high-resolution MS. After incubation of
PTEN with H2O2 or bpV-phen, samples were treated with
iodoacetamide to protect free cysteine thiols. This was
followed by tryptic digestion in the absence of reducing
agent to preserve existing disulfide bridges. Resulting pep-
tides were analyzed by MS. H2O2 and bpV-phen treatment
resulted in the formation of a tryptic fragment with a mono-
isotopic mass of 930.918 Th (MH4+) which was absent in the
untreated sample. MS/MS sequencing of this peak (Figure S7)
identified a fragment consisting of two peptides linked by
a disulfide between C124 and C71 (Figure 2b). Subsequent
treatment of the tryptic mixture with DTT led to a complete
loss of the corresponding isotope pattern (Figure 2c), verify-
ing disulfide formation. This confirms oxidative inhibition of
PTEN by bpV-phen.
To elucidate the structural consequences of disulfide
formation, we applied protein crystallography. The so far only
available crystal structure of PTEN shows the active site in its
reduced state (PDB: 1D5R) and was generated using
a truncated version of PTEN that involves its central
phosphatase and C2 domain (tPTEN, 7–353 aa with
a sequence deletion from 286 to 309).[17] To ensure applic-
ability of tPTEN for our studies, we confirmed that treatment
with H2O2 as well as bpV-phen results in the same disulfide-
bridged tryptic fragment observed for full-length PTEN
(Figures S8 and S9). We identified crystallization conditions
similar to that previously reported,[17] which provided crystals
diffracting with a resolution of up to 2.2 è. tPTEN crystallizes
in a space group distinct from the original structure (C2221 vs.
I4) with a significantly larger unit cell harboring four PTEN
molecules per asymmetric unit (Figure S10). The four proto-
mers align closely with each other (maximal RMSD= 1.46 è
for 314 Ca atoms) and with the previous PTEN structure
(maximal RMSD= 1.29 è, Figures S11 and S12). As reported
before, the active site is bound to one molecule of tartrate
originating from the crystallization buffer (Figure S13).
Having obtained suitable tPTEN crystals, we proceeded
with soaking experiments to study structural changes upon
H2O2 treatment. Crystals were incubated with 1 mm H2O2 for
1 h providing a crystal structure with 2.4 è resolution that
appears to be very similar to the reduced form of tPTEN
(maximal RMSD= 1.57 è for 314 Ca atoms, Figure 3a and
S14). While the electron density between catalytic cysteine
C124 and adjacent C71 is clearly separated before H2O2
treatment (Figure 3b), it is evidently connected after expo-
sure to H2O2 (PTEN(ox), Figure 3c). The oxidized active site
still harbors one molecule of tartrate.[18] Disulfide formation
promotes a rotation of catalytic cysteine C124 toward C71
without changing the position of their Ca atoms significantly
(Ca–Ca distance reduced: 5.2 è vs. oxidized: 5.0 è). Also, the
entire active site including the P-loop (IHCKAGKGRT)
displayed only minimal conformational changes (RMSD=
0.37 è for 10 Ca atoms, Figure 3d). This is in analogy to
human lymphoid tyrosine phosphatase (LYP) which also
Figure 2. a) Inhibition of PTEN (100 mm) by H2O2 (3.5 mm, blue) or
bpV-phen (400 mm, orange) is reversed by thiols (T=25 8C, 4 mm DTT
or GSH, triplicates, errors account for 1s ; *** P<0.001). b) Tryptic
fragment with disulfide between C71 and C124 (Th: Thomson=Da/e).
c) High-resolution MS spectra of tryptic fragment (Figure 2b) after
H2O2 (1 mm, blue) or bpV-phen (1 mm, orange) treatment (T=25 8C,
100 mm PTEN, t=10 min; upper panels). The fragment is absent in
the untreated control (black) and after incubation with 10 mm DTT
(lower panels, for details see Figure S6).
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exhibits small conformational changes in the P-loop upon
disulfide formation (RMSD= 0.39 è, Figure S15).[19] The
reversibly oxidized human PTPs, CDC25B (disulfide,
RMSD= 2.48 è),[20] and PTP1B (sulfenyl-amide, RMSD=
2.38 è)[21] exhibit substantial structural changes upon oxida-
tion (Figure S15). These PTPs also experience irreversible
oxidation of the active site cysteine (sulfinic or sulfonic acid)
upon long incubation times with H2O2 (t> 20 min).
[20,21] To
investigate the reversibility of PTEN oxidation, we performed
time-dependent activity measurements with increased H2O2
concentrations (Figure S4). Notably, reactivation upon DTT
treatment occurred up to 20 mm H2O2 and 80 min incubation
time, verifying the absence of irreversible modifications and
indicating very efficient protection of PTEN from constitutive
inactivation by oxidative agents.
Next, we employed 51V NMR spectroscopy to investigate
the reaction of bpV-phen with PTEN. bpV-Phen provided the
expected chemical shift (d(51V)=¢744 ppm)[22] and was
titrated (50–200 mm) to full-length PTEN (100 mm). At low
inhibitor concentration (50 mm), the bpV-phen signal rapidly
diminishes (complete conversion: < 15 min). This coincides
with the occurrence of the product peak (d(51V)=¢553 ppm)
which was assigned to dihydrogen orthovanadate (H2VO4
¢ ,
Figure 4a). At increased inhibitor concentrations (100 and
200 mm), we observed a residual bpV-phen signal indicating
quantitative oxidation of PTEN. To explore the structural
impact of PTEN oxidation by bpV-phen, tPTEN crystals were
soaked with 1 mm bpV-phen for 4 h. Since we were interested
in the precise localization of potential vanadium species,
crystallographic data collection was performed at a longer
wavelength (l= 1.77 è) allowing the detection of X-ray
diffraction as well as anomalous scattering originating only
from certain atoms such as vanadium and sulfur. We obtained
a crystal structure with 2.5 è resolution that appears to be
very similar to the structure after H2O2 treatment (maximal
RMSD= 1.37 è for 314 Ca atoms, Figure S16). The 2Fo¢Fc
omit map verifies disulfide formation with connected electron
densities between C124 and C71 in all four protomers
Figure 3. a) Superimposed structures of PTEN before (gray, PDB:
5BZZ, chain A) and after oxidation with H2O2 (blue, PDB: 5BUG, chain
A). b, c) Crystal structure of the active site in reduced and H2O2-treated
PTEN, respectively (both chain A). Side chains of C71 and C124 are
shown explicably (mesh: 2Fo¢Fc electron density omit map around
C71 and C124 contoured at 1s). d) Superimposed crystal structures of
active site residues of reduced (gray) and H2O2-treated (blue) PTEN.
Figure 4. a) 51V NMR titration measurements of bpV-phen (50–
200 mm) in the presence of full-length PTEN (100 mm). For complete
spectra see Figure S19. b–d) Crystal structures of the active site in
bpV-phen-treated (orange, PDB: 5BZX, b: chain A, c: chain: B) and
reduced PTEN (gray, PDB: 5BZZ, d: chain A). Orthovanadate and side
chains of C71 and C124 are shown explicably. Anomalous scattering
density map (mesh, contoured at 3.4s) was generated using the
Bijvoet difference Fourier method at a resolution of 5.0 ç (vanadium
and sulfur contribute to electron density). e) Superimposed structures
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(Figure S17). Based on the anomalous scattering signal, an
additional electron density map was generated applying the
Bijvoet difference Fourier method.[23] Under our conditions,
the resulting density is indicative for vanadium and sulfur
atoms. This map verifies disulfide formation in all protomers
and it shows additional anomalous density in the active site of
protomer A. This indicates the presence of a vanadium
species (Figure 4b) which together with the 2Fo¢Fc electron
density confirms the presence of orthovanadate (Figure S18).
Interestingly in chains B and D, the active site harbors one
molecule of tartrate analogous to the H2O2-treated crystals,
which is also reflected by a lack of the corresponding
anomalous signal. Chain C exhibits an intermediate state
with partial population by orthovanadate and tartrate (about
30:70). Despite the varying ligand occupancy, all four active
sites align closely (Figure S16). An overlay of reduced PTEN
(gray) with the H2O2 (blue) as well as bpV-phen (orange)
oxidized forms reveals minimal structural variations in the
active site indicating a low dependency of P-loop conforma-
tion on the oxidation state and the nature of the bound ligand
(Figures 4e and S17).
Orthovanadate binds to the active sites of numerous
enzymes including phosphatases and kinases.[24] To estimate
the affinity of orthovanadate for PTEN(ox), we performed
51V NMR experiments with preoxidized PTEN. In these
measurements, the orthovanadate peak neither exhibits line
broadening nor chemical shift changes, suggesting a very low
affinity (Kd> 1 mm, Figure S20). Taken together with the low
PTEN affinity of tartrate, this explains the presence of
orthovanadate, tartrate, and mixed states in the active site
during X-ray crystallography. Notably, orthovanadate inhibits
certain human phosphatases at sub-micromolar concentra-
tions (e.g. PTP1B (Ki= 0.38 mm),
[25] and alkaline phosphatase
(Ki= 0.6 mm)
[26]). For this reason, we were interested whether
it also contributes to PTEN inhibition by bpV-phen. In
activity assays using full-length PTEN and Na3VO4, we did
not detect phosphatase inhibition up to 0.1 mm orthovanadate
(Figure S5) and even at 1 mm Na3VO4 only 20% inhibition
was observed. This indicates that inhibition of PTEN by bpV-
phen is primarily induced by disulfide formation.
Herein, we show that H2O2 and bpV-phen inhibit PTEN
via reversible disulfide formation between cysteines C124 and
C71. In both cases, oxidation of PTEN results in only small
structural changes implying minimal impact on phosphatase-
independent functions. Reversible oxidation of active site
cysteines is a crucial feature for the regulation of many
phosphatases, including LYP,[19] PTP1B,[27] VHR,[27]
CDC25,[28] SHP-1/2,[29,30] LMW-PTP,[31] and PTEN.[32] For
reversible oxidation involving disulfide formation, two dis-
tinct cysteine arrangements are discussed based on the
relative distance of both cysteines within the primary
sequence:[19, 32] A) Cysteines are separated by only a few
amino acids (e.g. i,i+ 5 for LMW-PTP) and B) disulfide
formation occurs between two residues that are separated in
terms of sequence but located in close proximity. With respect
to the second case, CDC25B, LYP, and now PTEN have been
structurally characterized.[19,20] Compared with PTEN,
CDC25B exhibits severe structural changes upon reversible
oxidation with H2O2, whereas disulfide formation in LYP also
results in only minor structural changes. It remains to be seen
whether these differences in the conformation of the oxidized
state convey certain biological properties. For PTEN, it is
important to note that oxidative inhibition of phosphatase
activity appears to be highly reversible even after stringent
H2O2 treatment. This distinguishes PTEN from other studied
phosphatases and could indicate more efficient protection
from irreversible inactivation by reactive oxygen species.
The inhibition of PTEN by bpV-phen and H2O2 results in
the same oxidized protein species. However, the underlying
mechanisms differ since thiol oxidation by bpV complexes
involves an electron-transfer step rather than intermediate
formation of sulfenic acid.[33] The fact that inhibition of PTEN
by bpV-phen yields orthovanadate is an important finding
raising the question whether orthovanadate contributes to the
neuro- and cardioprotective effects of bpV complexes. In
addition, it remains to be seen whether the oxidative mode of
action observed for PTEN also applies for other phosphatases
thereby providing an explanation for the inhibitory effect of
bpV complexes on other PTPs.[13, 16] Finally, it is important to
note that the reversible inhibition of PTEN by bpV-phen may
represent a highly desirable feature for therapeutic applica-
tions since irreversible inhibition of this central tumor
suppressor holds the potential to induce systemic disturbance.
Acknowledgements
We thank Dr. Stefan Heinrichs for providing the PTEN gene
construct and Dr. Ingrid Vetter for support in the structure
determination. We thank Georg Holtermann and Franziska
Mîller for technical support in protein crystallography and
mass spectrometry, respectively. We thank Prof. Dr. Dieter
Lenz for initial support with 51VNMR spectroscopy, and Inke
Siewert for useful discussions. We appreciate the beamline
staff at Swiss Light Source PXII-X10SA. J.H. thanks the
Fonds der Chemischen Industrie for a PhD stipend. This work
was supported by the German Research Foundation (DFG,
Emmy Noether program RA1944/2-1 and GR3592/2-1),
AstraZeneca, Bayer CropScience, Bayer HealthCare, Boeh-
ringer Ingelheim, Merck KGaA, and the Max Planck Society.
Keywords: bpV-phen · disulfides · inhibitors ·
protein tyrosine phosphatase · tumor suppressors
How to cite: Angew. Chem. Int. Ed. 2015, 54, 13796–13800
Angew. Chem. 2015, 127, 14001–14005
[1] M. S. Song, L. Salmena, P. P. Pandolfi,Nat. Rev. Cancer 2012, 13,
283 – 296.
[2] F. Sun, K. K. Park, S. Belin, D. Wang, T. Lu, G. Chen, K. Zhang,
C. Yeung, G. Feng, B. A. Yankner, et al., Nature 2011, 480, 372 –
375.
[3] C. A. Worby, J. E. Dixon, Annu. Rev. Biochem. 2014, 83, 641 –
669.
[4] Z. Y. Zhang, J. E. Dixon, Biochemistry 1993, 32, 9340 – 9345.
[5] G. H. Peters, T. M. Frimurer, O. H. Olsen,Biochemistry 1998, 37,
5383 – 5393.
[6] N. K. Tonks, Nat. Rev. Mol. Cell Biol. 2006, 7, 833 – 846.
[7] C. C. Winterbourn, Nat. Chem. Biol. 2008, 4, 278 – 286.
Angewandte
Chemie
13799Angew. Chem. Int. Ed. 2015, 54, 13796 –13800 Ó 2015 The Authors. Published by Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim www.angewandte.org
[8] S. R. Lee, K. S. Yang, J. Kwon, C. Lee, W. Jeong, S. G. Rhee, J.
Biol. Chem. 2002, 277, 20336 – 20342.
[9] N. R. Leslie, D. Bennett, Y. E. Lindsay, H. Stewart, A. Gray, C. P.
Downes, EMBO J. 2003, 22, 5501 – 5510.
[10] U. Schwertassek, A. Haque, N. Krishnan, R. Greiner, L.
Weingarten, T. P. Dick, N. K. Tonks, FEBS J. 2014, 281, 3545 –
3558.
[11] A. Brunet, S. R. Datta, M. E. Greenberg, Curr. Opin. Neurobiol.
2001, 11, 297 – 305.
[12] A. C. Schmid, R. D. Byrne, R. Vilar, R. Woscholski, FEBS Lett.
2004, 566, 35 – 38.
[13] E. Rosivatz, J. G. Matthews, N. Q. McDonald, X. Mulet, K. K.
Ho, N. Lossi, A. C. Schmid, M. Mirabelli, K. M. Pomeranz, C.
Erneux, et al., ACS Chem. Biol. 2006, 1, 780 – 790.
[14] K. J. Christie, C. A. Webber, J. A. Martinez, B. Singh, D. W.
Zochodne, J. Neurosci. 2010, 30, 9306 – 9315.
[15] C. L. Walker, M. J. Walker, N.-K. Liu, E. C. Risberg, X. Gao, J.
Chen, X.-M. Xu, PLoS ONE 2012, 7, e30012.
[16] L. Spinelli, Y. E. Lindsay, N. R. Leslie,Adv. Biol. Regul. 2015, 57,
102 – 111.
[17] J. O. Lee, H. Yang, M. M. Georgescu, A. Di Cristofano, T.
Maehama, Y. Shi, J. E. Dixon, P. Pandolfi, N. P. Pavletich, Cell
1999, 99, 323 – 334.
[18] Given the fact that the active site harbors one molecule of
tartrate (Figure S13), we verified that tartrate does not affect
PTEN oxidation and reactivation under our assay conditions
(for details see Figure S3).
[19] S. J. Tsai, U. Sen, L. Zhao, W. B. Greenleaf, J. Dasgupta, E.
Fiorillo, V. Orrffl, N. Bottini, X. S. Chen, Biochemistry 2009, 48,
4838 – 4845.
[20] G. Buhrman, B. Parker, J. Sohn, J. Rudolph, C. Mattos,
Biochemistry 2005, 44, 5307 – 5316.
[21] A. Salmeen, J. N. Andersen, M. P. Myers, T.-C. Meng, J. A.
Hinks, N. K. Tonks, D. Barford, Nature 2003, 423, 769 – 773.
[22] Z. Cerovac, J. Ban, A. Morinville, K. Yaccato, A. Shaver, D.
Maysinger, Neurochem. Int. 1999, 34, 337 – 344.
[23] G. Strahs, J. Kraut, Annu. Rev. Biochem. 1968, 35, 503 – 512.
[24] J. Costa Pessoa, E. Garribba, M. F. A. Santos, T. Santos-Silva,
Coord. Chem. Rev. 2015, 301 – 302, 49 – 86.
[25] G. Huyer, S. Liu, J. Kelly, J. Moffat, P. Payette, B. Kennedy, G.
Tsaprailis, M. J. Gresser, C. Ramachandran, J. Biol. Chem. 1997,
272, 843 – 851.
[26] L. E. Seargeant, R. A. Stinson, Biochem. J. 1979, 181, 247 – 250.
[27] J. M. Denu, K. G. Tanner, Biochemistry 1998, 37, 5633 – 5642.
[28] J. Sohn, J. Rudolph, Biochemistry 2003, 42, 10060 – 10070.
[29] J. M. Cunnick, J. F. Dorsey, L. Mei, J. Wu, Biochem. Mol. Biol.
Int. 1998, 45, 887 – 894.
[30] T.-C. Meng, T. Fukada, N. K. Tonks,Mol. Cell 2002, 9, 387 – 399.
[31] A. Caselli, R. Marzocchini, G. Camici, G. Manao, G. Moneti, G.
Pieraccini, G. Ramponi, J. Biol. Chem. 1998, 273, 32554 – 32560.
[32] S. H. Cho, C. H. Lee, Y. Ahn, H. Kim, H. Kim, C. Y. Ahn, K. S.
Yang, S. R. Lee, FEBS Lett. 2004, 560, 7 – 13.
[33] F. P. Ballistreri, E. G. Barbuzzi, G. A. Tomaselli, R. M. Toscano,
J. Inorg. Biochem. 2000, 80, 173 – 176.
Received: July 9, 2015
Published online: September 29, 2015
.Angewandte
Communications
13800 www.angewandte.org Ó 2015 The Authors. Published by Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim Angew. Chem. Int. Ed. 2015, 54, 13796 –13800
